An approximately 2-fold increase in the plasma AUC of sitagliptin was observed in patients with moderate renal insufficiency, and an approximately 4-fold increase was observed in patients with severe renal insufficiency and in patients with ESRD on hemodialysis, as compared to normal healthy control subjects.
Mõõduka neerupuudulikkusega patsientidel täheldati sitagliptiini plasma AUC ligikaudu 2- kordset ning raske neerupuudulikkusega ja hemodialüüsi vajava lõppstaadiumis neeruhaigusega patsientidel ligikaudu 4- kordset suurenemist võrreldes tervete kontrollisikutega.